 Zentalis Pharmaceuticals Inc NASDAQ: ZNTL has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 12 trial evaluating ZN-c3 in patients with advanced solid tumors who are refractory to or ineligible for standard therapy or for whom no standard therapy is available. Data were presented at the American Association of Cancer Research AACR Annual Meeting. 